Free of Charge (FOC) Supply – Request for approval sent to NHS England [#]
Send to [redacted]

Medicines made available via pharmaceutical FOC schemes which have not yet been identified by the NHS England Early Access to Medicines Scheme (EAMS) must have this form completed for specialised medicines, and shared with the commissioner in order to obtain agreement to proceed with the scheme.

Completion of this form **does not** ensure future commissioning arrangements.

Trust Name	
Drug Name – Approved (and generic / biosimilar – if known)	
Preparation (strength and formulation)	
Drug Company	
UK license status	
Clinical indication	
Line in therapy and what this replaces (if any)	
Regimen (i.e. dose, route, duration and frequency, number of cycles Include all anticancer drugs and supportive care medication used in combination with FOC drug)	
Estimated number of anticipated patients per financial year	
Funding arrangements agreed with pharmaceutical company for existing patients if drug gains NICE approval	
Funding arrangements agreed with pharmaceutical company for existing patients if drug gains NICE approval but the patient does not fit the funding criteria	
Funding arrangements	

agreed with pharmaceutical company for existing patients if the drug does not gain marketing authorisation / NICE approval			
Trust activity – please detail number of attendances (outpatient, inpatient, follow-ups) required for the use of the drug			
Any other information/supporting evidence (level of evidence, phase of trial, protocol etc.)			
Requesting clinician			
Completed by:	**Name**	**email**	**Date**

Reference: https://www.sps.nhs.uk/wp-content/uploads/2018/07/FOC-medicine-scheme-policy-v-1.0Final.docx

Please note:

1. **NHS England does not generally commission the use of other medicines in combination with Free of Charge medicines. It is anticipated additional information and agreement may be required for any combination therapy.**
2. **A positive National Institute for Health Care Excellence Technology Appraisal (NICE TA) does not automatically mean that the responsible commissioner will pick up funding for patients already established on treatment. This would need discussion and agreement between pharmaceutical company and the responsible commissioner.**
3. **This form does not apply where a drug is used under a compassionate use scheme. For information the European Medicines Agency definition of a compassionate use scheme is: "Compassionate use is a treatment option that allows the use of an unauthorised medicine. Under strict conditions, products in development can be made available to groups of patients who have a disease with no satisfactory authorised therapies and who cannot enter clinical trials." This would normally apply to small numbers of patients and the medicine used would be unlicensed for the indication intended.**